Pharmaceutical company Biological E. Limited on 17.02.2020 launched its new plant, built with an investment of Rs. 300 crore at Genome Valley here.Telangana's Industry Minister K.T. Rama Rao inaugurated the facility, which will generate employment for about 1,000 people.

Mahima Datla, Managing Director, Biological E. Limited, this new facility will help their existing vaccines plant enhance the production and manufacture new products, which are in the pipeline.The plant has come up on 29 acres in the Special Economic Zone at Genome Valley in Kolthur village on the outskirts of Hyderabad.

Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, Professor Baron Peter Piot, Director, London School of Hygiene and Tropical Medicine were also present.

Rao said the government was committed to make Telangana number one state in terms of industrial growth and employment generation with a special focus on life sciences.Rama Rao also unveiled BE's Typhoid Conjugate Vaccine. Recently, BE received the authorisation from the health regulatory authorities of India to license and market TCV.

TCV is an injectable single-dose vaccine to be administered to children of the age of above 6 months as well as adults. The clinical studies conducted in India demonstrated that the safety and immunogenicity profiles of this vaccine are comparable to the other licensed and WHO Pre-qualified Typhoid conjugate vaccine, Biological E. said.

This vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Siena (Italy), which first developed the asset and transferred it to BE in 2013. Subsequent developmental work on the vaccine was done by BE, including manufacturing process optimization and scale up, pre-clinical studies and full clinical trials in India.

This vaccine will be manufactured in BE's GMP manufacturing facilities in Hyderabad, India and could be commercially available within 3 months, it added.

Story Source : IANS